SCYNEXIS, Inc. to Present at Canaccord Genuity Growth Conference 2014

Download as PDF

RESEARCH TRIANGLE PARK, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will present at the Canaccord Genuity Growth Conference 2014 at the InterContinental Boston on Wednesday, August 13, 2014, at 4:00 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

CONTACT: Company
         Chuck Osborne
         Chief Financial Officer
         Tel: 919-544-8600
         E-mail: chuck.osborne@scynexis.com

         Investor/Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com
Source: SCYNEXIS, Inc.

Released August 6, 2014